Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)

Tiziana Life Sciences TLSA is a biotechnology company establishing itself in a cutting-edge position in the market with its breakthrough immunomodulation therapies. The past six months have been an exciting time for the company, whose main drug candidate is the intranasally-delivered foralumab. Foralumab is the first fully human anti-CD3 monoclonal antibody (mAB), and it is able to effectively suppress neuroinflammation in the central nervous system.

The global market for mAB treatments was worth $210 billion in 2022, and it is expected to grow at a compound annual growth rate (CAGR) of 11% between 2023 and 2030. In 2023 a major development in the mAB market came when Sanofi SNY agreed to acquire Provention Bio for $2.9 billion for the anti-CD3 mAB, teplizumab. This acquisition revealed the biomedical market’s serious interest in anti-CD3 mAB therapies. 

Tiziana is currently focusing on foralumab’s potential to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS), as currently there are no Food and Drug Administration (FDA)-approved treatments for this condition available on the market. However, there are indications the drug has the potential to treat other central nervous system (CNS) diseases.  

Six Months In Review

Though movement in the drug development space is notoriously slow, Tiziana has met a series of major milestones in the past six months. The company has been running an open-label expanded access (EA) program for nonactive SPMS (naSPMS) patients, and it increased program enrollment from two to six patients in late 2022.

EA Program Results:

Other Applications For Foralumab: 

Tiziana also made a series of important announcements about other potential applications for foralumab. The company had an article published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS), which dived into intranasal Foralumab’s innovative mechanism of action (MoA) for reducing inflammation. Its MoA means foralumab has the potential to successfully treat a range of diseases.

Read more news stories about Tiziana Life Sciences on its website.

Featured photo by Hans Reniers on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksGeneralPartner ContentTiziana Life Sciences
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!